Kathleen N Moore

Kathleen N Moore

UNVERIFIED PROFILE

Are you Kathleen N Moore?   Register this Author

Register author
Kathleen N Moore

Kathleen N Moore

Publications by authors named "Kathleen N Moore"

Are you Kathleen N Moore?   Register this Author

100Publications

1956Reads

5Profile Views

Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].

Gynecol Oncol 2020 Feb 16;156(2):512-513. Epub 2019 Dec 16.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.12.007DOI Listing
February 2020

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

Gynecol Oncol 2020 Feb 6. Epub 2020 Feb 6.

Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, OK, USA; Sarah Cannon Research Institute, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.042DOI Listing
February 2020

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Gynecol Oncol 2020 Feb 18. Epub 2020 Feb 18.

Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.037DOI Listing
February 2020

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

N Engl J Med 2019 12 28;381(25):2403-2415. Epub 2019 Sep 28.

From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C.); University of Chicago Medicine (G.F.F.) and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University (D.C.), Chicago, and AbbVie, North Chicago (D.M.S., B.A.B., S.B., C.K.R., P.J.A., M.H.D.) - all in Illinois; NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo (M.F.B.), and Memorial Sloan Kettering Cancer Center, New York (K.B.-M., C.A.) - both in New York; University of Washington-Seattle Cancer Care Alliance, Seattle (E.M.S.); Lillebaelt University Hospital of Southern Denmark, Vejle, and the University of Southern Denmark, Odense (K.D.S.); Prince of Wales Clinical School, University of New South Wales and Royal Hospital for Women (M.F.), and the Northern Cancer Institute (S.B.-H.), Sydney; Jikei University School of Medicine, Tokyo (A. Okamoto), and Aichi Cancer Center Hospital, Nagoya (M.M.) - both in Japan; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (T.L.W.); Texas Oncology, U.S. Oncology Research Network, Fort Worth (N.G.C.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin); Women and Infants Hospital, Providence, RI (P.A.D.); Penn Medicine, Philadelphia (M.A.M.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.-H.N.); O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham (C.A.L.); Oxford University Hospitals, Oxford, United Kingdom (S.N.); Washington University School of Medicine, St. Louis (A.R.H.); Kaiser Permanente Northern California, San Francisco (R.D.L., M.A.B.); and H.M. Hospitales-Centro Integral Oncológico H.M. Clara Campal, Madrid (J.G.-D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1909707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941439PMC
December 2019

Olaparib in the treatment of ovarian cancer.

Future Oncol 2019 Oct 3;15(30):3435-3449. Epub 2019 Sep 3.

Division of Gynecologic Oncology, Stephenson Cancer Center at the University of Oklahoma HSC Oklahoma City, OK 73121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0271DOI Listing
October 2019

Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.

Front Oncol 2019 15;9:1067. Epub 2019 Oct 15.

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803528PMC
October 2019

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Gynecol Oncol 2019 08 4;154(2):294-301. Epub 2019 Jun 4.

Memorial Sloan Kettering Cancer Center New York, NY and Weill Cornell Medical College, New York, NY, United States of America. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.001DOI Listing
August 2019

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

J Natl Cancer Inst 2019 Jun;111(6):538-549

Medical Affairs, ImmunoGen Inc., Waltham, MA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/advance-article/doi/10.1093/jn
Publisher Site
http://dx.doi.org/10.1093/jnci/djz035DOI Listing
June 2019

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Gynecol Oncol 2019 05 12;153(2):436-444. Epub 2019 Feb 12.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.008DOI Listing
May 2019

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 May 1;20(5):636-648. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
May 2019

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Oncologist 2019 04 11;24(4):425-429. Epub 2019 Jan 11.

Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459241PMC
April 2019

Simple Hysterectomy for Cervical Cancer: Risk Factors for Failed Screening and Deviation From Screening Guidelines.

J Low Genit Tract Dis 2019 Apr;23(2):124-128

University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/LGT.0000000000000463DOI Listing
April 2019

Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.

Curr Opin Obstet Gynecol 2019 02;31(1):4-11

Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00001703-900000000-9928
Publisher Site
http://dx.doi.org/10.1097/GCO.0000000000000507DOI Listing
February 2019

Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12 1;32(6):1057-1071. Epub 2018 Oct 1.

Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Institute, The University of Oklahoma, 800 Northeast 10th Street, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183076
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.07.014DOI Listing
December 2018

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Clin Cancer Res 2018 11 29;24(22):5525-5533. Epub 2018 May 29.

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616528PMC
November 2018

Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.

Mol Cancer Ther 2018 10 19;17(10):2136-2143. Epub 2018 Jul 19.

Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1192DOI Listing
October 2018

Niraparib for the treatment of ovarian cancer.

Expert Rev Anticancer Ther 2018 08 2;18(8):727-733. Epub 2018 Jul 2.

a Division of Gynecologic Oncology , University of Oklahoma Stephenson Cancer Center , Oklahoma City , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1490180DOI Listing
August 2018

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Future Oncol 2018 Jul 9;14(17):1669-1678. Epub 2018 Feb 9.

Division of Hematology-Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0646DOI Listing
July 2018

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Clin Cancer Res 2018 07 10;24(14):3253-3262. Epub 2018 Apr 10.

Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3421DOI Listing
July 2018

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Gynecol Oncol 2018 06 24;149(3):605-611. Epub 2018 Apr 24.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.04.008DOI Listing
June 2018

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.

Gynecol Oncol 2018 04 4;149(1):214-220. Epub 2018 Feb 4.

Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.01.011DOI Listing
April 2018

Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.

Gynecol Oncol 2018 04;149(1):28-32

Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Section of Gynecologic Oncology, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.11.021DOI Listing
April 2018

Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.

Gynecol Oncol 2018 04;149(1):89-92

Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.10.023DOI Listing
April 2018

Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.

Gynecol Oncol 2018 03 10;148(3):601-608. Epub 2018 Jan 10.

Division of Gynecologic Oncology, Stevenson Oklahoma Cancer Center, Oklahoma City, OK, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.12.020DOI Listing
March 2018

Management of the toxicities of common targeted therapeutics for gynecologic cancers.

Gynecol Oncol 2018 03 1;148(3):591-600. Epub 2018 Feb 1.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.01.010DOI Listing
March 2018

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.

Clin Ther 2018 03 9;40(3):372-388. Epub 2018 Mar 9.

Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2018.01.005DOI Listing
March 2018

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Future Oncol 2018 Jan 3;14(2):123-136. Epub 2017 Nov 3.

Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0379DOI Listing
January 2018

Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.

Gynecol Oncol 2017 12 14;147(3):509-513. Epub 2017 Oct 14.

University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.10.007DOI Listing
December 2017

Factors influencing clinical trial enrollment among ovarian cancer patients.

Gynecol Oncol 2017 09 6;146(3):465-469. Epub 2017 Jul 6.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258173097
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2017.06.035DOI Listing
September 2017

Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.

Int J Gynecol Cancer 2017 05;27(4):730-737

*Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK; †NRG Oncology Statistics and Data Center, Roswell Park Cancer Institute, Buffalo, NY; and ‡Stephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000947DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407305PMC
May 2017

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

J Clin Oncol 2017 Apr 28;35(10):1112-1118. Epub 2016 Dec 28.

Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O'Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M. Bauer, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559878PMC
April 2017

Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.

Gynecol Oncol 2017 Jan 9;144(1):193-199. Epub 2016 Nov 9.

Stephenson Oklahoma Cancer Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.11.008DOI Listing
January 2017

Post-intensive care unit syndrome in gynecologic oncology patients.

Support Care Cancer 2016 11 15;24(11):4627-32. Epub 2016 Jun 15.

Department of Obstetrics & Gynecology, Section of Gynecologic Oncology, University of Oklahoma, 800 NE 10th Street Suite 5040, Oklahoma City, OK, 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3305-0DOI Listing
November 2016

The pro-inflammatory effect of obesity on high grade serous ovarian cancer.

Gynecol Oncol 2016 10 15;143(1):40-45. Epub 2016 Jul 15.

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.07.103DOI Listing
October 2016

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2016 10 8;34(28):3460-73. Epub 2016 Aug 8.

Alexi A. Wright, Dana-Farber Cancer Institute, Harvard Medical School; Don S. Dizon, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Deborah K. Armstrong, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Michael A. Bookman, US Oncology Research and Arizona Oncology, Tucson, AZ; William A. Cliby, Mayo Clinic, Rochester, MN; Robert L. Coleman and Larissa A. Meyer, The University of Texas MD Anderson Cancer Center, Houston, TX; Joseph J. Kash, Edward Cancer Center, Naperville; Jessica Oldham, Society of Gynecologic Oncology, Chicago, IL; Kathleen N. Moore, Stephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK; Alexander B. Olawaiye, University of Pittsburgh Medical Center, Pittsburgh; Mitchell I. Edelson, Hanjani Institute for Gynecologic Oncology, Abington Hospital, Jefferson Health, Abington, PA; Ritu Salani, The Ohio State University, Columbus, OH; Dee Sparacio, Hightstown, New Jersey; William P. Tew, Memorial Sloan-Kettering Cancer Center, New York, NY; and Ignace Vergote, Leuven Cancer Institute, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.6907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512594PMC
October 2016

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.

Oncologist 2016 08 2;21(8):954-63. Epub 2016 Jun 2.

Department of Obstetrics and Gynecology, University of Arizona Cancer Center-Phoenix, Creighton University School of Medicine at Dignity Health, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978548PMC
August 2016

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Invest New Drugs 2016 06 9;34(3):290-9. Epub 2016 Mar 9.

Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0336-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859861PMC
June 2016

BRACAnalysis CDx as a companion diagnostic tool for Lynparza.

Expert Rev Mol Diagn 2015 13;15(9):1111-6. Epub 2015 Aug 13.

a University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Division of Gynecologic Oncology, 800 NE 10th Street, Suite 5040, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2015.1078238DOI Listing
May 2016

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Gynecol Oncol 2016 May 11;141(2):260-263. Epub 2016 Mar 11.

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844793PMC
May 2016

Initiation of a formalized precision medicine program in gynecologic oncology.

Gynecol Oncol 2016 Apr;141(1):24-8

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.02.024DOI Listing
April 2016

Epithelial ovarian cancer in older women: defining the best management approach.

Am Soc Clin Oncol Educ Book 2015 :e311-21

From the University of Virginia, Charlottesville, VA; Memorial Sloan Kettering Cancer Center, New York NY; University of Oklahoma, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/11500311-156
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e311DOI Listing
February 2016

Is the NCI MATCH trial a match for gynecologic oncology?

Gynecol Oncol 2016 Jan 14;140(1):161-6. Epub 2015 Nov 14.

Stephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, United States.

View Article

Download full-text PDF

Source
http://ac.els-cdn.com/S009082581530175X/1-s2.0-S009082581530
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S009082581530175
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2015.11.003DOI Listing
January 2016

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Future Oncol 2015 ;11(5):747-57

University of Oklahoma Health Sciences Center, Stephenson Oklahoma Cancer Center, 800 NE 10th Street, Suite 5040, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.313DOI Listing
November 2015

Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?

J Clin Oncol 2015 Jul 18;33(19):2125-8. Epub 2015 May 18.

Stephenson Oklahoma Cancer Center, University of Oklahoma, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.0998DOI Listing
July 2015

Comprehensive care in gynecologic oncology: The importance of palliative care.

Gynecol Oncol 2015 May 4;137(2):193-202. Epub 2015 Mar 4.

University of Washington Medical Center, 1949 NE Pacific St., Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.02.026DOI Listing
May 2015

A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.

Int J Gynecol Cancer 2015 Mar;25(3):484-92

*Summa Cancer Institute, Summa Health System, Akron, OH; †NRG Oncology/Gynecologic Oncology Group Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY; ‡Case Western Reserve University, Cleveland, OH; §UT Southwestern Medical Center, Dallas, TX; ∥University Hospitals Case Medical Center, Cleveland, OH; ¶University of Washington, Seattle, WA; #University of Iowa, Iowa City, IA; **Decatur Memorial Hospital, Cancer Care Specialists of Central Illinois, Decatur, IL; ††Virginia Commonwealth University, Richmond, VA; and ‡‡Oklahoma University Health Science Center, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336206PMC
March 2015

Central nervous system metastasis in gynecologic cancer: symptom management, prognosis and palliative management strategies.

Gynecol Oncol 2015 Mar;136(3):472-7

Division of Gynecologic Oncology, University of Oklahoma, Stephenson Cancer Center, 800 NE 10th Street Suite 5050, Oklahoma City, OK 73104, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.12.020DOI Listing
March 2015

PARP inhibition in ovarian cancer: state of the science.

Gynecol Oncol 2015 Jan;136(1):8-10

University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 NE 10th Street, Suite 5040, Oklahoma City, Oklahoma 73104. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.12.009DOI Listing
January 2015

Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.

Curr Oncol Rep 2014 Nov;16(11):412

Department of Obstetrics and Gynecology, Oklahoma University Health Sciences Center, 800 N.E. 10th Street, Oklahoma, OK, 73103, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-014-0412-2DOI Listing
November 2014

The survival detriment of venous thromboembolism with epithelial ovarian cancer.

Gynecol Oncol 2014 Jul 1;134(1):73-7. Epub 2014 May 1.

University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.04.046DOI Listing
July 2014

The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study.

Gynecol Oncol 2014 Apr;133(1):23-7

University of Oklahoma, Department of Obstetrics & Gynecology, Section of Gynecologic Oncology, Oklahoma City, OK, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.01.041DOI Listing
April 2014

Referrals to phase I clinical trials in a gynecologic oncology unit.

Gynecol Oncol 2014 Jan 14;132(1):231-5. Epub 2013 Sep 14.

University of Oklahoma Health Sciences Center, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.09.003DOI Listing
January 2014

Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.

Gynecol Oncol 2014 Jan 9;132(1):50-4. Epub 2013 Nov 9.

Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.11.005DOI Listing
January 2014

Vaginal cancer: the experience from 2 large academic centers during a 15-year period.

J Low Genit Tract Dis 2013 Oct;17(4):409-13

1Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma, Oklahoma City, OK; and 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/LGT.0b013e3182800ee2DOI Listing
October 2013

Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?

Gynecol Oncol 2013 Sep 20;130(3):411-5. Epub 2013 Jun 20.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 71304, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.06.018DOI Listing
September 2013

Distance traveled for treatment of cervical cancer: who travels the farthest, and does it impact outcome?

Int J Gynecol Cancer 2013 Jul;23(6):1099-103

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ijgc/2013/07000/Distance_Travel
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e3182989464DOI Listing
July 2013

A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia.

Am J Obstet Gynecol 2013 May 1;208(5):410.e1-6. Epub 2013 Feb 1.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2013.01.047DOI Listing
May 2013

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Gynecol Oncol 2013 Apr 20;129(1):22-7. Epub 2012 Dec 20.

Dept. of Reproductive Medicine, Moores Cancer Center, University of California, San Diego School of Medicine, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.12.022DOI Listing
April 2013

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Gynecol Oncol 2012 Dec 7;127(3):456-61. Epub 2012 Sep 7.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.08.030DOI Listing
December 2012

Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.

Gynecol Oncol 2011 Sep 12;122(3):527-31. Epub 2011 Jun 12.

University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.05.022DOI Listing
September 2011

Uterine papillary serous carcinoma.

Clin Obstet Gynecol 2011 Jun;54(2):278-91

Department of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00003081-201106000-000
Publisher Site
http://dx.doi.org/10.1097/GRF.0b013e318218c755DOI Listing
June 2011